1.Therapeutic Observation of Electroacupuncture plus Muscle Energy Technique for Upper Crossed Syndrome
Jiajia HUA ; Jiajia SHI ; Aiming SHEN
Shanghai Journal of Acupuncture and Moxibustion 2017;36(1):81-84
Objective To observe the clinical efficacy of electroacupuncture plus muscle energy technique (MET) in treating upper crossed syndrome (UCS).Method Forty UCS patients were randomized into a treatment group and a control group, 20 cases in each group. The control group was intervened by electroacupuncture, while the treatment group was treated with MET to relax and regulate the cervical and shoulder muscles in addition to electroacupuncture. The two groups were treated once a day, for 3 weeks in total. The Visual Analogue Scale (VAS), Neck Disability Index (NDI), Hamilton Depression Scale (HAMD) and Pittsburgh Sleep Quality Index (PSQI) were observed before and after the intervention, and the clinical efficacies were compared between the two groups.Result After the treatment, the VAS, NDI, HAMD, and PSQI scores were significantly changed in both groups (P<0.05). The scores of all parameters in the treatment group were significantly different from those in the control group (P<0.05). The total effective rate was 95.0% in the treatment group versus 85.0% in the control group, and the between-group difference was statistically significant (P<0.05).Conclusion Electroacupuncture plus MET can improve the pain, depression, sleep disorder, and the quality of life of UCS patients.
2.Treatment of Hypertensive Intracerebral Hemorrhage by Minimal Invasive Puncture:A Time Window Study
Xiaochun SHEN ; Zhen WANG ; Yongjun CHEN ; Xiaoming JIANG ; Jiianjun HE ; Aiming CHEN ; Jinlin LI
International Journal of Cerebrovascular Diseases 2008;16(8):565-570
Objective:To study the best opportunity for minimal invasive puncture in the treatment of hypertensive intracerebral hemorrhage.Methods:Forty-one patients with hypertensive intracerebral hemorrhage were randomly divided into four groups:<6 h,6-12 h,12-18 h and 18-24 h from the onset of symptoms.The comparison among groups in outcome measures were performed,including the rebleeding rate,short-term efficacy,long-term efficacy,mortality,and excellent and good rate.Results:The incidence of complication such as rebleeding etc had no significantly difference in the four groups.The excellent and good rates of clinical outcomes at 3 months were the<6 h group>6-12 h group,and 12-18 h group>18-24 h group(P<0.05).The 18-24 h group had the highest mortality(30%,3/10).Conclusions:Within 6 h after the onset of hypertensive intracerebral hemorrhage was the best opportunity for the minimal invasive puncture.
3. Occupational activity disorders of extremely severe mass burn patients in recovery period after injury: a cross-sectional survey
Jiajia SHI ; Aiming SHEN ; Ying SUN ; Yajun LI ; Sainan WANG ; Shanshan PAN ; Zhou LI ; Long JIAO
Chinese Journal of Burns 2018;34(9):624-628
Objective:
To observe the distribution of occupational activity disorders of extremely severe mass burn patients in recovery period after injury.
Methods:
From December 2014 to December 2015, 65 extremely severe burn patients conforming to the inclusion criteria involved in August 2 Kunshan factory aluminum dust explosion accident were admitted to Kunshan Rehabilitation Hospital. They received comprehensive rehabilitation treatment after burns, including wearing pressure clothes, ultrasound treatment, semiconductor laser and red light irradiation, motor function training, and so on. Over 2 years after injury, a cross-sectional survey was conducted on the patients′ occupational activity disorders. Modified Barthel index (MBI) was used to assess the degree of activities of daily living (ADL) disorder of patients and to grade the independent level of completing each item of MBI, and then the independent level of patients completing self-care MBI items (bathing, dressing, grooming, eating, going to the toilet, urine control, and stool control) was compared with that of mobility items (going up and down stairs, bed and chair transfer, and walking). The Canadian Occupational Performance Measure (COPM) was used to assess the distribution of occupational activity disorders of patients. The distribution of the five most serious occupational activity disorders was counted, then the frequency and probability of which with frequency greater than or equal to 16 times were calculated. Data were processed with Pearson Chi-square test.
Results:
Over 2 years after injury, the MBI score of patients was (76±22) points, and the ADL of 83.08% (54/65) patients reached completely self-care or light ADL disorder level. The MBI items arranged according to the completing independent level of patients from high to low were urine control/stool control, walking, bed and chair transfer, going up and down stairs, going to the toilet, eating, grooming, dressing, and bathing. The independent level of patients completing self-care MBI items was lower than that of mobility items (
4.Influence of Cyclophosphamidum Used in Different Time during Menstrual Cycle on Ovary Anti-mullerian Hormone
Zhu SHEN ; Junjie BAO ; Ying ZENG ; Guowen CAO ; Aiming SHI ; Hong TAO ; Bin CAO ; Feng XU
China Pharmacist 2018;21(1):121-123
Objective:To preliminarily discuss the difference of ovary anti-miillerian hormone ( AMH) when cyclophosphamide is used in different time during menstrual cycle .Methods:Totally 30 young female patients with average age of (36 ±6.39) diagnosed as glomerular disease were treated with cyclophosphamide .According to the medication time , the patients were divided into follicular phase group and secretory phase group based on the property of menstrual cycle .Follicular phase group was treated with cyclophospha-mide during the first day and the eighth day of menstrual cycle .Secretory phase group was treated with cyclophosphamide after ovulato-ry time, namely the 14th day-the 16th day of menstrual cycle.AMH was detected before the drug treatment and 1st, 3rd, 6th and 10th cycles after cyclophosphamide treatment in the two groups .Results: AMH in the five periods had no statistic difference between the groups (P>0.05).There was significant difference in AMH before the treatment and after one-month treatment in the same group(P<0.05).AMH in different age groups showed statistic difference (P<0.05).Conclusion:There is no significant difference in AMH when cyclophosphamide is administrated in different time of menstrual cycle .However , ovarian function is impaired just by low dose cyclophosphamide (0.8g) with the first administration and will be recovered slowly at least half a year after the drug withdrawal .
5. Outcomes of 138 myelodysplastic syndrome patients with HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation
Qianqian WANG ; Zixian LIU ; Xiaoli ZHAO ; Guixin ZHANG ; Jianfeng YAO ; Xiaohui ZHENG ; Lining ZHANG ; Yuyan SHEN ; Xingli ZHAO ; Yi HE ; Yong HUANG ; Rongli ZHANG ; Jialin WEI ; Qiaoling MA ; Aiming PANG ; Donglin YANG ; Weihua ZHAI ; Erlie JIANG ; Sizhou FENG ; Mingzhe HAN
Chinese Journal of Hematology 2020;41(2):132-137
Objective:
To evaluate the outcomes of myelodysplastic syndromes (MDS) patients who received HLA-matched sibling donor allogeneic peripheral blood stem cell transplantation (MSD-PBSCT) .
Methods:
The clinical data of 138 MDS patients received MSD-PBSCT from Sep. 2005 to Dec. 2017 were retrospectively analyzed, and the overall survival (OS) rate, disease-free survival (DFS) rate, relapse rate (RR) , non-relapse mortality (NRM) rate and the related risk factors were explored.
Results:
①After a median follow-up of 1 050 (range 4 to 4 988) days, the 3-year OS and DFS rates were (66.6±4.1) % and (63.3±4.1) %, respectively. The 3-year cumulative incidence of RR and NRM rates were (13.9±0.1) % and (22.2±0.1) %, respectively. ②Univariate analysis showed that patients with grade Ⅲ-Ⅳ acute graft-versus-host disease (aGVHD) or hematopoietic cell transplantation comorbidity index (HCT-CI) ≥2 points or patients in very high-risk group of the Revised International Prognostic Scoring System (IPSS-R) had significantly decreased OS[ (42.9±13.2) %
6.Oral sulfate solution versus polyethylene glycol for colonoscopy bowel preparation: a randomized controlled study in phase Ⅲ
Ye ZONG ; Fandong MENG ; Yongdong WU ; Bangmao WANG ; Xizhong SHEN ; Yi CUI ; Guoxin ZHANG ; Aiming YANG ; De'an TIAN ; Jianting CAI ; Huahong WANG ; Shihua CUI ; Min CUI ; Shutian ZHANG
Chinese Journal of Digestive Endoscopy 2022;39(4):261-266
Objective:To compare the efficacy of oral sulfate solution (OSS) and polyethylene glycol (PEG) electrolyte powder for colonoscopy bowel preparation.Methods:A total of 283 randomized patients from 9 centers in China taking OSS ( n=143) or PEG ( n=140) using two-day split bowel preparation regimen received colonoscopy and assessment. The primary index was the bowel preparation success rate [global Boston bowel preparation scale (BBPS)≥ 6 by independent assessment center]. Secondary indices included BBPS global and segmental scores, investigator satisfaction (5-point Likert scale) with the quality of bowel preparation, patient satisfaction assessed by questionnaires, and patient tolerance assessed by Sharma scale. Compliance and safety were compared between the two groups. Results:The bowel preparation success rates were 100.0% for OSS and 99.3% for PEG [adjusted difference 0.7% (95% CI: -5.3% - 6.7%), P<0.001 for non-inferiority]. The BBPS global score in OSS group was significantly higher than that in PEG group (8.1 VS 7.7, P<0.001). The segment BBPS scores were also higher in OSS group than those in PEG group for all 3 segments (right colon: 2.4 VS 2.3, P=0.002; transverse colon: 2.8 VS 2.7, P=0.018; left colon: 2.8 VS 2.7, P=0.007). Investigator Likert score in the OSS group was significantly higher than that in the PEG group (2.6 VS 2.3, P<0.001). There was no significant difference in compliance between OSS and PEG, except for the second dose (90.9% VS 82.6%, P=0.039). There was no significant difference in patient satisfaction, Sharma score or proportion of patients with tolerance-related symptoms between the two groups. Safety was comparable between the two groups, and all adverse events were mild to moderate. Conclusion:OSS has comparable efficacy with PEG, with higher BBPS scores in all segments, better investigator satisfaction, better compliance in split dose, and comparable patient tolerance and safety.
7.Comparison of outcomes of adult acute lymphoblastic leukemia patients underwent autologous and allogeneic hematopoietic stem cell transplantation.
Yuyan SHEN ; Shulian CHEN ; Donglin YANG ; Yi HE ; Erlie JIANG ; Jialin WEI ; Yong HUANG ; Rongli ZHANG ; Qiaoling MA ; Aiming PANG ; Xin YANG ; Zhao WANG ; Junjie CUI ; Lukun ZHOU ; Xin CHEN ; Sizhou FENG ; Mingzhe HAN
Chinese Journal of Hematology 2015;36(3):210-215
OBJECTIVETo compare the outcomes of adult patients with acute lymphoblastic leukemia (ALL) who underwent autologous hematopoietic stem cell transplantation (auto-HSCT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT).
METHODSFrom Jan 2007 to Dec 2010, 106 adult ALL patients were retrospectively divided into two groups, 50 in auto-HSCT group and 56 in allo-HSCT group. Auto-HSCT group included 21 patients with high-risk, 46 patients in CR1 and 4 cases in CR2. All the 50 patients had negative minimal residual disease (MRD) prior to HSCT. Allo-HSCT group included 44 patients with high risk, 51 patients in CR1 and 5 cases in CR2, 15 patients with positive MRD before allo-HSCT. response, regulatory T cells (Treg), cytokines levels and treatment-related adverse effects were observed.
RESULTSOf the total 106 patients, 29 patients relapsed at a medium follow-up of 22.9(0.8-63.3) months. The 3-year cumulative relapse rate (RR) was (29.9±8.0) % in auto-HSCT group and (32.7±6.8) % in allo-HSCT group. There were no significant differences in RR and overall survival (OS) between auto-HSCT and allo-HSCT groups, even of stratified risk groups. In standard risk group, 3-year OS was (77.1±13.2) % in auto-HSCT group and (90.9±8.7) % in allo-HSCT group (P=0.739). In high-risk group, 3-year OS was (68.7±10.8) % after auto-HSCT and (45.2±8.5) % after allo-HSCT (P=0.094).
CONCLUSIONDue to acceptable RR and OS, adult ALL patients with no MRD before HSCT showed favorable survival. Auto-HSCT may be a considerable choice for adult ALL patients with negative MRD when lacking of donors for allo-HSCT.
Adult ; Allografts ; Hematopoietic Stem Cell Transplantation ; Humans ; Neoplasm, Residual ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; Recurrence ; Retrospective Studies ; Transplantation, Homologous